22:15 , Aug 2, 2018 |  BC Innovations  |  Tools & Techniques

Model firsts

By combining disparate data into coherent mechanistic models, quantitative systems pharmacology is becoming a key tool for picking the right dose for first-in-human trials and other early make-or-break decisions. Advocates see it as part of...
18:44 , Oct 6, 2017 |  BC Week In Review  |  Company News

Sumitomo grants Maruishi rights to FAAH inhibitor

Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) granted Maruishi Pharmaceutical Co. Ltd. (Osaka, Japan) exclusive development and commercialization rights to a preclinical fatty acid amide hydrolase (FAAH) inhibitor. The compound is testing in the U.S. and...
21:32 , Sep 29, 2017 |  BC Week In Review  |  Financial News

SpringWorks launches with $103M series A

On Sept. 25, SpringWorks Therapeutics LLC (New York, N.Y.) spun out of Pfizer Inc. (NYSE:PFE) with a tranched $103 million series A round led by Bain Capital Life Sciences, Bain Capital Double Impact and OrbiMed....
21:00 , Sep 29, 2017 |  BioCentury  |  Finance

Spring cleaning

SpringWorks Therapeutics LLC aims to partner with pharmas and big biotechs seeking a development path for clinical stage assets outside of their core therapeutic areas. With its tranched $103 million series A round, the newco...
11:02 , Sep 25, 2017 |  BC Extra  |  Financial News

SpringWorks launches with $103M series A

SpringWorks Therapeutics LLC (New York, N.Y.) spun out of Pfizer Inc. (NYSE:PFE) with a tranched $103 million series A round led by Bain Capital Life Sciences, Bain Capital Double Impact and OrbiMed. Pfizer and LifeArc...
00:34 , Jun 9, 2017 |  BC Extra  |  Clinical News

Team describes off-target effects of Bial's FAAH inhibitor

In a paper published in...
00:44 , Jan 31, 2017 |  BC Extra  |  Politics & Policy

Bioethicists: Consider efficacy before human trials

In a commentary published Monday in...
23:15 , Nov 15, 2016 |  BC Extra  |  Politics & Policy

EMA updates first-in-human guidance

In newly released draft guidance , EMA outlined revised strategies to identify and reduce risks in first-in-human testing, emphasizing the use of non-clinical pharmacokinetic, pharmacodynamic and toxicology data in forming risk assessments. The guidance took...
07:00 , Aug 12, 2016 |  BC Extra  |  Clinical News

FDA: Bial-Portela's FAAH inhibitor has "unique toxicity"

In its safety review of fatty acid amide hydrolase ( FAAH ) inhibitors, FDA concluded that BIA 10-2474 from Bial-Portela & Ca. S.A. (S. Mamede do Coronado, Portugal) "exhibits a unique toxicity that does not...
07:00 , Aug 4, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Fatty acid amide hydrolase (FAAH)

Dermatology INDICATION: Wounds Cell culture and mouse studies suggest FAAH inhibitors or the FAAH substrates N-acyl-taurines could help treat wounds. In primary human keratinocytes, a FAAH inhibitor tool compound increased cell migration and markers of...